We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.


Clear all

Refine your search

Content type

9 results found


AA Thornton | United Kingdom, European Union | 25 Jun 2019

Biosimilars and patents

Biosimilars are biological products which are highly similar in structure, biological activity, efficacy, safety and immunogenicity profile to


AA Thornton | European Union | 11 Jun 2018

Assessment of “plausibility” requirement from the EPO perspective

This article considers how the EPO views the requirement of “plausibility”, which can arise during both the assessment of “sufficient disclosure” of


AA Thornton | USA, United Kingdom, European Union | 13 May 2018

CRISPR: the gene editing tool and related patents

CRISPR (clustered regularly interspaced short palindromic repeats) gene-editing technology is considered as one of the biggest innovations of the


AA Thornton | European Union | 13 Jul 2017

European patents no longer available for plants and animals obtained exclusively by means of an essentially biological process

A key change has recently been implemented under European Patent Law in order to exclude from patentability, plants and animals “exclusively” obtained


AA Thornton | European Union | 12 Jul 2017

Change of Rules 27 and 28 regarding patentability of plants and animals at the EPO

A key change has been implemented in Rules 27 and 28 EPC in order to exclude plants and animals “exclusively” obtained by essentially biological


AA Thornton | United Kingdom | 15 Sep 2014

Eli Lilly v Human Genome Sciences Ltd

UK High Court denies Eli Lilly's request to prevent Human Genome Sciences Ltd from obtaining a Supplementary Protection Certificate for the human


AA Thornton | United Kingdom | 27 Aug 2013

Stop right there! UK Court of Appeal grants interim injunction on a patent previously found to be invalid

In a recent decision, the UK Court of Appeal has overturned an earlier decision of the High Court and granted Novartis AG an interim injunction to

Previous page 1 Next page